Internal Medicine, Endocrinology, Diabetes, & Metabolism · East Brunswick, NJ
NPI
1871798579
Since 2007
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
9 Auer Ct Ste A
East Brunswick, NJ, 08816
Phone (732) 390-6666
Groups this clinician bills Medicare through
Medicare paid, 2024
$513K
23,297 services
Medicare patients, 2024
500
Average age 75
Drug cost, 2024
$3.2M
5,551 prescriptions
Company payments, 2025
$555
From 14 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Matthew L Surgan was code J0897 (injection, denosumab, 1 mg), 4,620 times for 44 patients. In total Matthew L Surgan billed 23,297 services in 61 codes, and Medicare paid $513K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-07-21.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 4,620 | 44 | $20.37 | $94K |
| 82172 Clinical Chemistry | Office | 1,198 | 249 | $20.53 | $25K |
| 99214 Office E&M - Established | Office | 957 | 427 | $112.99 | $108K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 893 | 374 | $14.24 | $13K |
| 36415 Venipuncture Blood Collection | Office | 864 | 369 | $8.26 | $7,133 |
| 80053 Clinical Chemistry | Office | 794 | 340 | $10.27 | $8,151 |
| 84481 Clinical Chemistry | Office | 786 | 340 | $16.50 | $13K |
| 83735 Clinical Chemistry | Office | 784 | 340 | $6.53 | $5,120 |
| 86800 Immunoassay | Office | 784 | 338 | $15.50 | $12K |
| 86376 Immunoassay | Office | 784 | 338 | $14.17 | $11K |
| 82728 Clinical Chemistry | Office | 784 | 339 | $13.28 | $10K |
| 84443 Clinical Chemistry | Office | 775 | 336 | $16.36 | $13K |
| 85025 Blood Count | Office | 775 | 336 | $7.56 | $5,861 |
| 84439 Clinical Chemistry | Office | 772 | 334 | $8.79 | $6,783 |
| 82746 Clinical Chemistry | Office | 650 | 338 | $14.34 | $9,320 |
By year: 2022 $387K for 15,926 services; 2023 $436K for 19,638 services; 2024 $513K for 23,297 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 82172 Clinical Chemistry | 1,198 | 249 | $20.53 | $25K |
| 36415 Venipuncture Blood Collection | 864 | 369 | $8.26 | $7,133 |
| 80053 Clinical Chemistry | 794 | 340 | $10.27 | $8,151 |
| 84481 Clinical Chemistry | 786 | 340 | $16.50 | $13K |
| 86800 Immunoassay | 784 | 338 | $15.50 | $12K |
| 86376 Immunoassay | 784 | 338 | $14.17 | $11K |
| 83735 Clinical Chemistry | 784 | 340 | $6.53 | $5,120 |
| 82728 Clinical Chemistry | 784 | 339 | $13.28 | $10K |
| 84443 Clinical Chemistry | 775 | 336 | $16.36 | $13K |
| 85025 Blood Count | 775 | 336 | $7.56 | $5,861 |
Medicare prescription drug claims, 2024
In 2024, the drug Matthew L Surgan prescribed most often to Medicare patients was Levothyroxine Sodium, with 515 prescriptions and refills. In total Matthew L Surgan wrote 5,551 Medicare prescriptions that cost $3.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 515 | 1,439 | 135 | $6,669 |
| Ozempic Semaglutide | 467 | 878 | 104 | $818K |
| Rosuvastatin Calcium Generic | 419 | 1,171 | 126 | $8,480 |
| Jardiance Empagliflozin | 321 | 657 | 72 | $369K |
| Synthroid Levothyroxine Sodium | 300 | 801 | 79 | $27K |
| Metformin Hcl Er Metformin Hcl | 262 | 762 | 78 | $4,692 |
| Repaglinide Generic | 215 | 550 | 65 | $15K |
| Ezetimibe Generic | 212 | 566 | 62 | $6,162 |
| Farxiga Dapagliflozin Propanediol | 172 | 434 | 54 | $231K |
| Atorvastatin Calcium Generic | 146 | 430 | 43 | $2,311 |
| Trulicity Dulaglutide | 118 | 225 | 27 | $217K |
| Mounjaro Tirzepatide | 117 | 148 | 22 | $153K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 112 | 299 | 37 | $14K |
| Losartan Potassium Generic | 89 | 264 | 28 | $1,028 |
| Metformin Hcl Generic | 89 | 241 | 23 | $1,096 |
Brand drugs: 2,818 claims; generic drugs: 2,481 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Matthew L Surgan $555 ($555 in general payments such as food, travel and fees) from 14 companies. The largest payer was Novo Nordisk Inc with $154.
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc NVO | 16 | $154 |
| Abbvie Inc. ABBV | 5 | $77.7 |
| Sanofi-Aventis U.S. LLC SNY | 3 | $53.38 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $45.88 |
| Abbott Laboratories ABT | 2 | $40.03 |
| Sequel Med Tech, LLC | 1 | $27.42 |
| Dexcom, Inc. DXCM | 1 | $26.77 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 1 | $23.18 |
| Acella Pharmaceuticals, LLC | 1 | $20.2 |
| Novartis Pharmaceuticals Corporation NVS | 1 | $19.06 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.